Treatment-related myelodysplastic syndrome after temozolomide for recurrent high-grade glioma

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Journal of Neuro-Oncology

• Publication date

  2005-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s11060-004-2028-0PMID 15735923
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972.

  2003cited by this paper
• Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide.

  2002cited by this paper
• Thalidomide for the treatment of patients with myelodysplastic syndromes

  2002cited by this paper
• Thalidomide Paradoxical Effect on Concomitant Multiple Myeloma and Myelodysplasia

  2002cited by this paper
• Temozolomide for recurrent high-grade glioma.

  2001cited by this paper
• Partial deletions of the long and short arm of chromosome 3 point to two tumor suppressor genes in uveal melanoma.

  2001cited by this paper
• Comparative genomic hybridization reveals frequent losses of chromosomes 1p and 3q in pheochromocytomas and abdominal paragangliomas, suggesting a common genetic etiology.

  2000cited by this paper
• Myelodysplastic Syndrome Following Treatment of Malignant Melanoma with Vincristine, ACNU, and Dacarbazine

  2000cited by this paper
• Temozolomide in malignant gliomas.

  2000cited by this paper
• A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

  2000cited by this paper
• Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials.

  1999cited by this paper
• Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group.

  1999cited by this paper
• Secondary myeloid/natural killer cell precursor acute leukemia following essential thrombocythemia.

  1999cited by this paper
• Genetic instabilities in human cancers

  1998cited by this paper
• Secondary myelodysplasia and acute leukemia in breast cancer patients after autologous bone marrow transplant.

  1998cited by this paper
• Acute leukemia following treatment of malignant glioma

  1998cited by this paper
• Aetiology of acute leukaemia.

  1997cited by this paper
• Therapy-related myeloid leukemia.

  1996cited by this paper
• Primary vs. secondary neoplasia‐associated chromosomal abnormalities—balanced rearrangements vs. genomic imbalances?

  1996cited by this paper
• Therapy-related chronic myelomonocytic leukaemia with bone marrow eosinophilia associated with der(11)t(1;11)(q21;q14).

  1996cited by this paper
• Allelotype analysis in osteosarcomas: frequent allele loss on 3q, 13q, 17p, and 18q.

  1992cited by this paper
• Risk of leukemia after chemotherapy and radiation treatment for breast cancer.

  1992cited by this paper
• Late toxicities and complications in three-year survivors of small cell lung cancer.

  1991cited by this paper
• Leukemia in a child with a history of medulloblastoma.

  1991cited by this paper
• Leukemia in a child with a history of medulloblastoma.

  1991cited by this paper
• Poor survival of treatment-related acute nonlymphocytic leukemia.

  1990cited by this paper
• Leukaemia complicating treatment for Hodgkin's disease: the experience of the British National Lymphoma Investigation.

  1990cited by this paper
• Therapy-related leukemia and myelodysplastic syndrome: clinical, cytogenetic, and prognostic features.

  1986cited by this paper
• Leukemia after adjuvant chemotherapy with semustine (methyl-CCNU)--evidence of a dose-response effect.

  1986cited by this paper
• Carmustine as a cause of acute nonlymphocytic leukemia.

  1985cited by this paper
• Carmustine as a cause of acute nonlymphocytic leukemia.

  1985cited by this paper
• Acute nonlymphocytic leukemia following treatment of malignant glioma. Report of two cases.

  1984cited by this paper
• Two cases of acute leukemia following treatment of malignant glioma

  1983cited by this paper
• Acute nonlymphoblastic leukemia in a patient treated for brain tumor.

  1982cited by this paper
• Clinical toxicity of combined modality treatment with nitrosourea derivatives for central nervous system tumors.

  1982cited by this paper
• Nonrandom chromosome abnormalities in acute leukemia and dysmyelopoietic syndromes in patients with previously treated malignant disease.

  1981cited by this paper
• Effect of 1-(4-amino-2-methylpyrimidin-5-yl)methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride on leukemia L-1210(Communication)

  1974cited by this paper

• Comprehensive understanding of the adverse effects associated with temozolomide: a disproportionate analysis based on the FAERS database

  2024cites this paper
• Occurrence of non-central nervous system cancers during postoperative follow-up of patients who underwent surgery for a WHO grade II glioma: implications for therapeutic management

  2023cites this paper
• Temozolomide duration and secondary hematological neoplasms: A literature review and implications for patients with neuroendocrine neoplasms

  2022cites this paper
• Supramolecular Hydrogel Based Post-Surgical Implant System for Hydrophobic Drug Delivery Against Glioma Recurrence

  2022cites this paper
• Mediastinal Mass in a Brain Tumor Patient Treated with Chemotherapy: Lymphoma after Temozolomide

  2019cites this paper
• Second primary cancers in long-term survivors of glioblastoma.

  2019cites this paper
• Acute lymphoblastic leukemia following temozolomide treatment in a patient with glioblastoma: A case report and review of the literature.

  2018cites this paper
• A Case of Therapy-Related Acute Myeloid Leukemia Associated with Adjuvant Temozolomide Chemotherapy for Anaplastic Astrocytoma.

  2017cites this paper
• Haematological malignancies following temozolomide treatment for paediatric high-grade glioma.

  2017cites this paper
• Brain tumors - other treatment modalities.

  2017cites this paper
• Recurrent glioblastoma: a single-institution experience with reirradiation and temozolomide

  2017cites this paper
• Temozolomide induces the expression of the glioma Big Potassium (gBK) ion channel, while inhibiting fascin-1 expression: possible targets for glioma therapy

  2016cites this paper
• Fatal Liver and Bone Marrow Toxicity by Combination Treatment of Dichloroacetate and Artesunate in a Glioblastoma Multiforme Patient: Case Report and Review of the Literature

  2016cites this paper
• Featuring Author , Key Word and Full-Text Search Member of the Spectrum of Side Effects of Anticonvulsants in Patients with Brain

  2016cites this paper
• Aging of hematopoietic stem cells: DNA damage and mutations?

  2016cites this paper
• Stem Cell-Specific Mechanisms Ensure Genomic Fidelity within HSCs and upon Aging of HSCs.

  2015cites this paper
• Temozolomide in Advanced Neuroendocrine Neoplasms: Pharmacological and Clinical Aspects

  2015cites this paper
• An early and rare second malignancy in a treated glioblastoma multiforme: is it radiation or temozolomide?

  2015cites this paper
• Treatment-related Acute Myeloid Leukaemia After Temozolomide for Glioblastoma Multiforme.

  2014cites this paper
• Nanoparticle based strategies for the treatment of Glioblastoma

  2014cites this paper
• Secondary hematological malignancies associated with temozolomide in patients with glioma.

  2013cites this paper
• Non-Hodgkin Lymphoma after Treatment with Extended Dosing Temozolomide and Radiotherapy for a Glioblastoma: A Case Report

  2013cites this paper
• A Patient With Glioblastoma Who Died From Lung and Pleural Lesions With Rapid Progression: Synchronous Double Primary Malignant Tumors

  2013cites this paper
• Temozolomide-Related Hematologic Toxicity

  2013cites this paper
• Temozolomide-related idiosyncratic and other uncommon toxicities: a systematic review

  2012cites this paper
• Spectrum of Side Effects of Anticonvulsants in Patients with Brain Tumours

  2012cites this paper
• Treatment-related myelodysplasia in patients with primary brain tumors.

  2012cites this paper
• The role of temozolomide in the treatment of aggressive pituitary adenomas and pituitary carcinomas

  2012cites this paper
• Phase II Trial of Temozolomide in Patients with Relapsed Sensitive or Refractory Small Cell Lung Cancer, with Assessment of Methylguanine-DNA Methyltransferase as a Potential Biomarker

  2012cites this paper
• Non‐Hodgkin's lymphoma in a patient on treatment with temozolomide

  2012cites this paper
• Hematologic adverse events associated with temozolomide

  2011cites this paper
• Dose‐dense temozolomide regimens

  2010cites this paper
• Temozolomide: therapeutic limitations in the treatment of adult high-grade gliomas

  2010cites this paper
• The role of post-translation regulation of Twist expression in the tumor progression of squamous cell carcinoma of head and neck

  2010cites this paper
• Targeting O6-methylguanine-DNA methyltransferase with specific inhibitors as a strategy in cancer therapy

  2010cites this paper
• Temozolomide-Induced Myelodysplasia

  2010cites this paper
• Cytostatic and cytotoxic drugs

  2010cites this paper
• Acute lymphoblastic leukemia after temozolomide treatment for anaplastic astrocytoma in a child with a germline TP53 mutation

  2010cites this paper
• Acute lymphoblastic leukemia subsequent to temozolomide use in a 26-year-old man: a case report

  2010cites this paper
• Seizures in low- and high-grade gliomas: current management and future outlook

  2010cites this paper
• Temozolomide treatment for aggressive pituitary tumors: correlation of clinical outcome with O(6)-methylguanine methyltransferase (MGMT) promoter methylation and expression.

  2010cites this paper
• Tonsillary carcinoma after temozolomide treatment for glioblastoma multiforme: treatment-related or dual-pathology?

  2009cites this paper
• Possible leukemogenic potential of temozolomide

  2009cites this paper
• Therapy-related myelodysplastic syndrome/acute myeloid leukemia after treatment with temozolomide in a patient with glioblastoma multiforme.

  2009cites this paper
• Dacarbazine induced acute myeloid leukemia in melanoma.

  2009cites this paper
• Temozolomide in malignant gliomas: current use and future targets

  2009cites this paper
• Recent approaches to improve the antitumor efficacy of temozolomide.

  2009cites this paper
• Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required

  2009cites this paper
• Non‐Hodgkin lymphoma following temozolomide

  2009cites this paper
• Long-term use of temozolomide: could you use temozolomide safely for life in gliomas?

  2009cites this paper
• Secondary neoplasms following treatment for brain tumors.

  2009cites this paper
• Late effects of treatment for brain tumors

  2009cites this paper
• Team of Excellence Research Program I. General Information

  2009cites this paper
• Recurrent metastatic neuroblastoma followed by myelodysplastic syndrome: Possible leukemogenic role of temozolomide

  2008cites this paper
• Non-Hodgkin's lymphoma in patients with glioma treated with temozolomide.

  2008cites this paper
• Genetic diagnosis of alveolar rhabdomyosarcoma in the bone marrow of a patient without evidence of primary tumor

  2008cites this paper
• O6-Methylguanine-DNA methyltransferase inactivation and chemotherapy.

  2008cites this paper
• Gliomes de grade II

  2008cites this paper
• Treatment-related Myelodysplastic Syndrome After Temozolomide Use in a Child: First Report

  2008cites this paper
• Extended exposure to alkylator chemotherapy: delayed appearance of myelodysplasia

  2008cites this paper
• The impact of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomas.

  2007cites this paper
• Prolonged and severe myelosuppression in two patients after low-dose temozolomide treatment- case study and review of literature

  2007cites this paper
• Temozolomide and Radiation in Low-Grade and Anaplastic Gliomas: Temoradiation

  2007cites this paper
• Novel therapies for malignant gliomas.

  2007cites this paper
• The safety of the temozolomide in patients with malignant glioma.

  2006cites this paper
• Treatment-related myelodysplastic syndrome after chemotherapy for childhood low-grade astrocytoma.

  2006cites this paper
• Role of O6-methylguanine-DNA methyltransferase in protecting from alkylating agent-induced toxicity and mutations in mice.

  2006cites this paper
• Metronomic Dosing of Chemotherapy: Applications in Pediatric Oncology

  2006cites this paper
• For Peer Review Role of O 6 -methylguanine-DNA methyltransferase in protecting from alkylating agent-induced toxicity and mutations in mice

  2006cites this paper
• Treatment-related myelodysplasia/AML in a patient with a history of breast cancer and an oligodendroglioma treated with temozolomide: case study and review of the literature.

  2006cites this paper
• Irinotecan plus temozolomide for relapsed or refractory neuroblastoma.

  2006cites this paper
• Glioma Therapy in Adults

  2006cites this paper
• N euro- O ncology Low-Grade Gliomas in Adults

  2006cites this paper
• Low-grade gliomas in adults.

  2006cites this paper
• Mutagenic potential of temozolomide in bone marrow cells in vivo.

  2005cites this paper
• Current awareness: Pharmacoepidemiology and drug safety

  2005cites this paper
• Secondary Ph+ acute lymphoblastic leukemia after temozolomide

  2005cites this paper